July 8, 2025
Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Notice of Acceptance for Presentation at the 84th Annual Meeting of the Japanese Cancer Association

We are pleased to announce that the results of our joint research with UBE Corporation (Head Office: Minato-ku, Tokyo, President: Yuki Nishida) have been accepted for a poster session at the 84th Annual Meeting of the Japanese Cancer Association (to be held September 25-27, 2025).

At this annual meeting, we plan to present the high anti-tumor efficacy of PPMX-T004b-PGAP-1 and its comparison with pre-existing products in a poster session.

Title: "Evaluation of Efficacy of a Novel Antibody-Drug Conjugate PPMX-T004b-PGAP-1 Targeting CDH3 in Solid Tumors, and Comparative Study with pre-existing products"
Session: I-P13-6 Antibody-Drug Conjugate Therapy
Authors: Sayuri Kaneko*, Hiroko Akiyoshi*, Shimpei Nonouchi**, Takashi Matsushita**, Takamasa Kashiwagi**, Gen Mizuno**, Yukinori Wada**, Megumi Hikichi*, Yoichi Aikawa*, Shinji Hagiwara*
(*Perseus Proteomics Inc., **UBE Corporation)
Presentation date and time: September 27, 2025, 15:30–17:00 (scheduled)
Venue: Ishikawa Ongakudo, Hotel Nikko Kanazawa, ANA Crowne Plaza Kanazawa, etc.

About PPMX-T004b-PGAP-1
PPMX-T004b-PGAP-1 is an antibody-drug conjugate (ADC) targeting cadherin 3 (CDH3), which is highly expressed in various solid tumors such as ovarian cancer, biliary tract cancer, and head and neck squamous cell carcinoma. It is one of the PPMX-T004 ADCs currently under development, aiming to optimize efficacy and toxicity.

About the Japanese Cancer Association
The Japanese Cancer Association was established with the aim of contributing to national health and welfare by promoting the development of cancer research through research presentations and exchange of knowledge on cancer science and its applications, as well as by fostering collaboration among members and with related academic societies both domestically and internationally.

End